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Background: Pharmaceutical marketing is undergoing a major shift in the United States, in part due to new transparency
regulations under the healthcare reform act. Changes in pharmaceutical marketing practices include a possible shift from
more traditional forms of direct-to-consumer advertising towards emerging use of Internet-based DTCA (“eDTCA”) given
the growing importance of digital health or “eHealth.” Though legally allowed only in the U.S. and New Zealand, eDTCA
poses novel regulatory challenges, as it can cross geopolitical boundaries and impact health systems and populations
outside of these countries.
Methods: We wished to assess whether changes in DTCA and eDTCA expenditure trends was occurring using publicly
available pharmaceutical marketing data. DTCA data was analyzed to compare trends in aggregate marketing
expenditures and to assess if there were statistically significant differences in trends and magnitudes for data sources
and DTCA sub-categories (including eDTCA). This was accomplished using regression lines of DTCA trend data and
conducting pairwise comparisons of regression coefficients using t-tests. Means testing was utilized for comparing
magnitude of DTCA expenditure.
Results: Data from multiple data sources indicate that aggregate DTCA expenditures have slightly declined during the
period from 2005–2009 and are consistent with results from other studies. For DTCA sub-categories, television remained
the most utilized form of DTCA, though experienced trends of declining expenditures (−13.2 %) similar to other traditional
media platforms such as radio (−30.7 %) and outdoor ads (−12.1 %). The only DTCA sub-category that experienced
substantial increased expenditures was eDTCA (+109.0 %) and it was the only medium that had statistically significant
differences in its marketing expenditure trends compared to other DTCA sub-categories.
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Conclusions: Our study indicates that traditional DTCA marketing may be on the decline. Conversely, the only DTCA
sub-category that experienced significant increases was eDTCA. However, to fully understand this possible shift to “digital”
DTCA, improvements in publicly available DTCA data sources are necessary to confirm changing trends and validate
existing data. Hence, utilizing the newly implemented U.S. physician-payment expenditure transparency requirements, we
advocate for the mandatory disclosure of DTCA/eDTCA in order to inform future domestic and international health policy
efforts regarding appropriate regulation of pharmaceutical promotion.
Keywords: Direct-to-consumer advertising, Sunshine act, Physician payments, Conflicts of interest, Health marketing and
promotion, Health policy, eHealthBackground
Pharmaceutical marketing is currently undergoing a unique
and understudied transition in the United States, the world’s
largest market for prescription drug sales [1]. In the 1990s,
expanding pharmaceutical industry marketing budgets ag-
gressively targeted physicians through deployment of tens of
thousands of pharmaceutical sales representatives and use of
other promotional strategies [2, 3]. During this same time
period, prescription drug spending experienced a nearly six-
fold increase from $40.3–$234.1 billion between 1990–2008
[4, 5]. The rapid rise in pharmaceutical marketing activities
was also accompanied by the emergence of a relatively new
and previously underutilized form of pharmaceutical pro-
motion, but one directed at the consumer, not the physician
[6, 7]. The emergence of direct-to-consumer advertising
(“DTCA”) in the late 1990s - a form of pharmaceutical mar-
keting that directly advertises prescription drugs and targets
the consumer/patient – represented a new opportunity for
industry marketing diversification and influencing prescrip-
tion drug sales and utilization [6–8]. Yet, this marketing
phenomenon is unique, as it is only permitted in the U.S.
and New Zealand among developed countries, though forms
of direct and indirect promotion to consumers (e.g., promo-
tional materials, reminder advertisements, “infomercials,”
and unbranded advertising campaigns) can occur outside
these two countries [6, 9–12].
Similar to forms of physician-directed promotion, DTCA
has been criticized as leading to inappropriate prescribing
(initiated by patients, not prescribers), overemphasis of ben-
efits versus risks in marketing claims, and overutilization of
prescription and branded drugs [13–18]. Due to these con-
cerns, criticism has been leveled against DTCA and calls for
limits have been explored, but have failed to gain traction
largely due to constitutional challenges in the U.S. on
restricting forms of commercial free speech [6, 13, 16]. In-
deed, calls for an outright ban on DTCA mimic the 25-year
old WHO Ethical Criteria for Medicinal Drug Promotion
that first recommended the general prohibition of DTCA
even before its popularization and widespread use in the
U.S. [19]. Additionally, DTCA has also gone through its
own changes as the regulatory and pharmaceutical marketenvironment around it has developed, including rapid ex-
pansion of use following liberalization of US Food and Drug
Administration (“FDA”) regulation/guidance in the 1980s
and late 1990s that lead to an estimated ~330 % increase in
expenditures from 1996–2005, but also experiencing recent
declines in expenditures following the global economic crisis
and patent expiration of a number of blockbuster drug
products [7, 12, 13, 20–22].
At the same time, a new era of digital health information-
seeking and behavior has given rise to new sub-categories
of DTCA - including DTCA that is Internet-based or
uses social media technology/platforms (“eDTCA”) -
that have not been well quantified or studied [9, 10, 23,
24]. Despite eDTCA’s potential to emerge as a more pre-
dominant health-marketing medium in this new era of
the “e-patient,” there remains a general lack of transpar-
ency of data reporting both DTCA and eDTCA expendi-
tures that is needed to assess emerging trends and
fundamental changes in health marketing strategies.
Hence, we wished to examine whether shifts in DTCA
and eDTCA expenditures were actually occurring. We
also wanted to assess whether there was adequate access
and availability to data reporting DTCA expenditures in
order to explore this question. Finally, we explore the po-
tential health policy implications and necessary solutions
to address the changing nature of DTCA.Methods
We first set out to identify publicly available data
sources that collect information about DTCA and
DTCA sub-category (including eDTCA) expenditures.
Such identification was consistent with methods previ-
ously reported in the literature [13, 20]. Specifically,
they include utilizing data from the following marketing
firms: IMS Health, Nielsen Co., Cegedim Strategic Data,
and Kantar Media (collectively “Marketing Firms”). Data
utilized for this study were either free or required a fee
to purchase (but were nevertheless accessible to the
general public and did not require a formal data request
or proposal for access.) We excluded data sources that
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tutional subscription fees, and/or fee-based academic/
research licenses generally not offered to the public. We
focused on data in the public domain as we wished to
assess the level of transparency of DTCA expenditure
information and whether such information was readily
available for public scrutiny absent the payment of
oftentimes expensive fees for licensing the data (com-
monly paid for by industry for market research pur-
poses) or submission of a proposal providing rationale
to access/license the data (which can be time intensive,
subject to certain use restrictions or pre-publication re-
view, and which could be rejected by a Marketing Firm.)
Though we did not seek data directly from Marketing
Firms, we note that a request for DTCA data and DTCA
sub-categories (such as eDTCA) generally requires a fee-
based license and formal data request proposal directly
with Marketing Firms. As an example, IMS Health has a
lengthy process for licensing data, which includes submit-
ting a detailed request, concept assessment, finalizing pro-
ject specifications, and finally contracting, payment, and
delivery. Overall, these requirements may make it difficult
or cost prohibitive to obtain DTCA expenditure data.
The majority of publicly available DTCA data exam-
ined was gathered through trade publications and/or
other formats (e.g. press releases, white papers, and
third-party licensee fee-based reports). All data sources
assessed in this study have been listed in Appendix
Table 1. Data collection methods utilized by these
sources were predominantly conducted using surveys of
national media outlets (including TV, radio, print, Inter-
net, etc.) and other media channels. In addition to Mar-
keting Firm non-peer reviewed reports, we also utilized
a recent publication by Kornfield et al. in the journal
PLoS One for comparison purposes as it is the most
comprehensive and up-to-date source on aggregate
pharmaceutical promotion expenditure [20]. Kornfield
et al. utilized Kantar Media and IMS Health as data
sources in their analyses. We examined data from 2005–
2009 in our DTCA expenditure analysis, as it was the only
time period where DTCA data were available forTable 1 Percentage change in categories of US DTCA expenditures
DTCA category 2005 expenditure/rank
Total televisiona $3,390,587,472 (1)
Total print mediab $1,320,786,065 (2)
Total radio outletsc $66,798,340 (3)
Outdoor ads $8,640,720 (5)
Internet $56,180,283 (4)
Total DTCA expenditure $4,842,992,880
Source: Nielsen Co. data sourced from fee-based PharmLive Report “Direct-to-Consu
aIncludes network, cable, syndicated, and spot TV ads. Excludes Spanish Language
bIncludes national magazine, local magazine, national Sunday supplement, local Su
cIncludes network and spot radio adsaggregate spending and for DTCA sub-categories exam-
ined/compared when this study was conducted.
Data were analyzed to assess trends (both increasing
and decreasing) in DTCA marketing expenditures and
to assess if there were statistically significant differences
in trends and magnitudes for data sources and DTCA
sub-categories. In order to assess overall expenditure
change for DTCA sub-categories over the five-year
period from 2005–2009, percentage change calculations
were conducted (Table 1). In order to assess statistically
significant differences in trends, regression lines were
computed for the series of years available from each data
source and each data category. Pairwise comparisons of
regression coefficients were then conducted using t-tests
(Tables 2 and 3). In order to assess statistically significant
differences in magnitude, means were computed for the
series of years available from each data source and each
data category. These means were then adjusted by estimat-
ing a common slope. t-Tests were then used to determine
if differences in magnitude were statistically significant.
Results
Information from multiple data sources indicate that aggre-
gate DTCA expenditures have slightly declined (−7.83 %)
during the period from 2005–2009. Additionally, Nielsen Co.
DTCA expenditure data was examined for an additional five
sub-categories of DTCA: television, print media, radio, out-
door marketing, and specifically Internet (i.e. eDTCA) with
differences reported in total expenditure and percentage in-
crease from 2005–2009 (Fig. 1). We excluded in our analysis
DTCA sub-categories of Spanish language TV and free
standing insert coupons as this data was not consistently col-
lected during the time period examined from data sources.
Television remained the largest sub-category of
DTCA expenditure in both 2005 and 2009, although it
exhibited a 13.20 % decline over that time period. Print
media was the second-largest type of DTCA expend-
iture in both 2005 and 2009; its expenditures remained
approximately the same, exhibiting only a 2.18 % in-
crease and it did not significantly differ from trends in
any other types of DTCA expenditure. Radio(2005–2009)
2009 expenditure/rank Percentage change (2005–2009)
$2,943,000,894 (−) −13.20 %
$1,349,517,112 (−) 2.18 %
$46,323,067 (4) −30.65 %
$7,598,381 (−) −12.06 %
$117,403,346 (3) 108.98 %
$4,463,842,800 −7.83 %
mer Advertising: Review and Outlook 2011”
TV DTCA expenditures
nday supplement, national newspaper, and local newspaper
Table 2 Pairwise statistical tests to determine (1) if trendline slopes for 2005–2009 DTCA data types were significantly different and
(2) if magnitudes for 2005–2009 DTCA data types were significantly different after adjusting for effect of time
Statistic TV vs. Print TV vs. Radio TV vs. Outdoor TV vs. Internet
Trend Δ (2nd minus 1st) -$122,609,071 -$146,138,808 -$154,272,982 -$167,279,709
SEdiff $94,728,227 $64,642,885 $64,409,125 $64,550,379
t −1.2943 −2.2607 −2.3952 −2.5915
df 6 6 6 6
p 0.2431 0.0645 0.0536 0.0411
Magnitude Δ (2nd minus 1st) -$1,706,354,882 -$3,137,268,387 -$3,177,916,521 -$3,099,469,979
SEdiff $140,278,912 $115,175,353 $117,948,373 $123,036,591
t −12.164 −27.2391 −26.9433 −25.1914
df 7 7 7 7
p <0.0001 <0.0001 <0.0001 <0.0001
Print vs. Radio Print vs. Outdoor Print vs. Internet Radio vs. Outdoor Radio vs. Internet Outdoor vs. Internet
$23,529,737 -$31,663,911 -$44,670,638 -$8,134,174 -$21,140,901 -$13,006,727
$69,692,386 $69,475,618 $69,606,591 $5,668,070 $7,095,286 $4,491,759
0.3376 −0.4558 −0.6418 −1.4351 −2.9796 −2.8957
6 6 6 6 6 6
0.7471 0.6646 0.5448 0.2013 0.0247 0.0275
$1,430,913,505 -$1,471,561,639 -$1,393,115,097 -$40,648,133 $37,798,408 $78,446,542
$92,111,455 $92,526,092 $94,212,421 $8,601,111 $14,628,702 $9,106,204
15.5346 −15.9043 −14.787 −4.7259 2.5839 8.6146
7 7 7 7 7 7
<0.0001 <0.0001 <0.0001 0.0021 0.0363 <0.0001
Note: TV expenditures reported exclude Spanish TV DTCA
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penditure in 2005 and the fourth-largest type of DTCA
expenditure in 2009, exhibiting a 30.65 % decline. Out-
door marketing expenditure was the smallest type of
DTCA expenditure in both 2005 and 2009, exhibiting a
12.06 % decrease (Table 2).Table 3 Pairwise statistical tests to determine (1) if trendline
slopes for 2005–2009 Internet DTCA data sources were significantly
different and (2) if magnitudes for 2005–2009 Internet DTCA data
sources were significantly different after adjusting for effect of time
Statistic Nielson vs. Kantar









p 0.0229Internet expenditure was the fourth-largest type of
DTCA expenditure in 2005 and the third-largest type of
DTCA expenditure in 2009. It was also the only DTCA
sub-category to experience a triple-digit increase (108.98 %)
in expenditure (with print DTCA only experiencing a mod-
est 2.18 % increase over the same time period). Its upward
trend was the only expenditure data significantly different
from the downward trends of expenditures in television
(p = 0.0411), radio (p = 0.0247), and outdoor (p = 0.0275)
types of DTCA (Table 2). Kantar Media also reported
upward trends for Internet DTCA expenditure.
Though all sources reported an upward trend in
eDTCA, Kantar Media reported a significantly higher
amount (+$107,111,591) of Internet DTCA expenditure
than Nielsen Co. (p = 0.0229) (See Fig. 2 and Table 3).
From a data source comparison perspective, Nielsen
Co. did not report a significantly different magnitude of
total DTCA expenditure than Kantar Media (p = 0.5144).
Furthermore, significant differences in magnitude did not
exist between IMS Health and Nielsen Co. (p = 0.3145),
IMS Health and Kantar Media (p = 0.0971), Nielsen Co.
and data from the Kornfield et al. PLoS One study (p =
0.073), and Kantar Media and PLoS One (p = 0.2495).
The only significant difference in reporting of total
Fig. 1 Total DTCA Expenditure (USD$) by Category vs. Percentage Change (%) (2005-2009)
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Health and PLoS One (p = 0.017), in which IMS Health
reported a $620,666,667 lower magnitude of DTCA ex-
penditure than the PLoS One study. All data sources re-
ported that DTCA expenditures first increased and then
decreased over the time period reviewed and no signifi-
cant difference in total, overall DTCA expenditure
trends was detected.
Discussion
Our examination indicates that the expenditure trend in
traditional forms of DTCA (TV, print, radio) is statistically
significantly different than that for eDTCA. Specifically,
while traditional media types of DTCA expenditure has
been diminishing, eDTCA expenditure has experienced
three-digit percentage growth, though admittedly remains
much lower in absolute spending compared to other his-
torically dominant sub-categories of DTCA (primarily TVbroadcast). However, given the popularity and increasing
use of the Internet to search for and consume health in-
formation, it is not unreasonable to expect that increases
in eDTCA expenditures will continue, though without re-
liable data, the growth and impact may not fully be under-
stood [9, 10, 23].
Further, some observed lack of agreement across different
data sources for DTCA expenditure indicates that there is
a general absence of consistent, accessible, and high-quality
data needed for future health policy and regulatory
decision-making when assessing the changing use and im-
pact of DTCA [1]. Despite a general alignment of aggregate
DTCA expenditure and the trend directionality, lack of ro-
bust disclosure of DTCA expenditure and the sampling
methodology used to collect such data makes comparisons
difficult to validate. Despite these limitations, we neverthe-
less were able to identify that declining trends in aggregate
DTCA spending contrasted with a rise of Internet-based
Fig. 2 Internet DTCA Expenditure Based on Source (2005-2009)
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to know the exact magnitude.
While declines in aggregate DTCA are largely unsurpris-
ing, given recent challenges faced by the pharmaceutical in-
dustry and the US economy during the global financial
crisis that led to declines in overall marketing budgets [20],
our findings showing an increase in eDTCA expenditures
seem to run contrary to these general market trends. Spe-
cifically, even during financially straining periods, increases
in eDTCA may indicate that marketers are simply retarget-
ing their promotion to where consumers increasingly seek
and consume health information and products: online. In-
deed, reflecting this potential trend, the Pew Internet Re-
search estimates 72 % of adult users now actively search for
health information online [23]. In addition, US healthcare
and pharmaceutical online advertisement spending was
predicted to experience double-digit percent growth from
2010–2015 [10]. Hence, our findings may simply reflect a
trend of increasing utilization of the Internet by health con-
sumers and its resultant effect of shifting drug advertising
away from traditional forms of DTCA to eDTCA that may
also be cheaper and more accessible for marketers [1, 25].
Most importantly, increases in US-based eDTCA expend-
iture may also pose unique global public policy concerns that
have yet to be adequately assessed. Specifically, eDTCA has
already been identified as easily transmitting over geopoliticalborders via satellite TV, the Internet, and social media, con-
sequentially becoming “globalized” given that it is dissemi-
nated and can be easily accessed by consumers worldwide
[10, 25, 26]. Lack of access to robust data to make meaning-
ful comparisons between DTCA and eDTCA expenditure
trends further inhibits any ability to appropriately assess the
international spread of eDTCA and its impact on popula-
tions outside of the U.S. and New Zealand, the only two de-
veloped markets where it is legally permissible [6, 27, 28].
This could lead to negative impacts on public health out-
comes and national prescription drug expenditures in coun-
tries where such promotion is legally prohibited but not
contained nor identified as a possible public policy problem
[6, 10]. Additionally, existing regulatory frameworks address-
ing traditional DTCA may be ineffectual when responding
to the rapid advances of Internet-based technologies and the
dynamic engagement and interaction elements of social
media based eDTCA [9, 10]. Specifically, the development of
regulations and technical tools needed to legally limit dis-
semination within the U.S. market have not kept pace up
with the rise of new eDTCA platforms, offerings, and various
channels of consumer engagement [9].
Policymaking challenges include ongoing efforts by the
FDA, which is struggling to formulate a regulatory
framework to address social media-based DTCA. Steps
taken by the FDA include issuing draft guidance
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advertising to be balanced, accurate and non-misleading;
requiring manufacturers to disclose benefit and risk in-
formation even when limited character space is available;
how to respond to requests for off-label information;
and addressing how firms should correct misinformation
about their products posted by third-parties [29]. While
still in draft form, several pharmaceutical firms and trade
groups (including PhRMA and BIO), have been highly
critical of FDA’s approach in this space, with finalization
of FDA guidance still in progress following completion
of a public comment period [30].
In addition, lack of sufficient eDTCA regulation can also
enable clearly illicit online marketing that harms patients
[31]. An example is the growth of illicit online pharmacies,
which use their own forms of fraudulent and misleading
eDTCA to illegally sell pharmaceutical products without
prescriptions directly to the consumer [31–35]. These
products may in fact be “falsified” or “fraudulent” (defined
as medicines made with criminal intent to deceive regard-
ing the authenticity or origin), as warned by the World
Health Organization (“WHO”) and various drug regulatory
agencies [9, 25, 36]. Consequentially, consumers may have
trouble differentiating between eDTCA originating from
fraudulent online pharmacies and eDTCA from authorized
manufacturers, thereby leading to potential patient safety
risks [31]. Organizations including the WHO, FDA, the
UN Office of Drugs and Crime, and Interpol have begun
to recognize the need for action against this dangerous
form of illicit global e-commerce, but have yet to target
eDTCA as a primary enabling factor and marketing
medium for consumer access [31]. This may in part be due
to the paucity of consistent data comparing legitimate and
illegal forms of eDTCA for policy development.
Hence, one crucial step in appropriately assessing the po-
tential health impacts of DTCA and its changing sub-
categories is requiring disclosure and transparency similar
to legal mandates for other forms of pharmaceutical mar-
keting [1, 31]. Taking lessons from the recent passage of
US Federal legislation under the Affordable Care Act that
now requires transparency and annual public disclosure of
certain marketing directed to physicians by drug, biologic
and medical device manufacturers (also known as the
“Sunshine” or transparency act provisions and OPEN PAY-
MENTS system), requiring mandatory disclosure of DTCA
and specifically of its sub-category of eDTCA, would pro-
vide important information in determining accurate DTCA
trends and consumer exposure [37, 38]. Instead of relying
on third party Marketing Firms with varying methods and
estimations that appear to have variation, expansion of
these transparency provisions to include DTCA disclosure
would allow data to be sourced directly from manufac-
turers, thereby allowing for better quality data and subse-
quently evidence-based policymaking to curb negativeimpacts of pharmaceutical marketing on consumers [1]. If
designed properly, this approach could identify specific
pharmaceutical classes/products that are heavily targeted
at consumers, types of eDTCA media/channels utilized,
identification of possible illegal off-label promotion activ-
ities, and importantly, finally provide information on the
geographic reach of DTCA spending outside of the USA
and New Zealand [1].
Limitations
The most significant limitation to the data we exam-
ined is that methodologies for data collection employed
by different Marketing Firms may not be consistent,
making it hard to assess whether data is comparable
and accurate. For example, when comparing Internet
DTCA Nielsen Co. expenditure data to Internet DTCA
Kantar Media data, we discovered variation [20]. Re-
ported Internet DTCA expenditure for the same 2005-
2009-time period (adjusted for 2010 Consumer Price
Index – All Urban), showed significant differences in
expenditure amounts (p = 0.0229). We report that
Kantar Media Internet DTCA expenditures’ 2005–2009
trend is not significantly different than Nielsen Co.
Internet DTCA expenditures’ 2005–2009 trend (p =
0.8554), as the former’s overall increase is 72 % and the
latter’s overall increase is 90 %. However, the result of
this statistical test does not convey the widely fluctuat-
ing year-to-year variations in reported DTCA expendi-
tures between these two data sources, which range
from $23 million in 2007 to $191 million in 2009, with
an average difference of over $100 million. In addition,
methodologies for collecting eDTCA may still be in mat-
uration and may vary based on marketing surveillance/
sampling methods. As an example, in 2010 Kantar Media
reported a substantial decline in Internet DTCA from
$312 to 202 million (2010 Nielsen Internet DTCA data
was not available for comparison). Accounting for this in
the overall growth trend would mean that Internet DTCA
expenditures experienced a more modest increase of
11.6 % from 2005–2010. This deduction would be a prob-
lem not only because it obscures the 72 % increases from
2005–2009, but also because this dramatic downturn
makes a deviation from other data sources more likely.
There are a number of reasons why reported Marketing
Firm data may report variation. This includes differences
in DTCA data collection methodology (i.e. media sampling
and channel monitoring strategies), differences in defining
the pharmaceutical market/DTCA mediums, and differ-
ences in methods for calculating expenditures. Overall
inconsistency between DTCA data sources creates barriers
in interpreting just how much spending is involved
in pharmaceutical eDTCA marketing and makes policy
analysis and public policy formulation all the more
challenging.
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21st century healthcare is increasingly becoming digital and
is changing the way clinicians, patients, and the broader glo-
bal public, search for and interpret information about their
health status and available treatment options. Hence, the
“digitization” and globalization of DTCA through forms of
eDTCA, requires further study to assess its potential impact
on both domestic and global healthcare outcomes, expendi-
tures, and appropriate utilization of prescription drugs. Yet,
current publicly available data on DTCA and eDTCA is ex-
tremely limited and lacks necessary validity to inform im-
portant health policy decisions. Better data is especially
needed given the rise, fall, and evolution of DTCA mediums
beginning with early print and radio ads, moving to national
TV commercials, and now the emergence of eDTCA with
the rise of the “Health Internet” and e-patient [10, 12, 39]. In
response, regulatory and transparency responses such as the
U.S. Sunshine Act that compels manufacturer disclosure,
may provide an important basis for establishing accurate and
evidence-based pharmaceutical policy that is adaptive and
can dynamically adjust to the changing nature of DTCA.Ethics approval and consent
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AppendixAppendix Table 1 Publicly-available expenditure data used in this
Category Source 2005 20
Aggregate DTCA IMS Health $4,251,000,000 $4
Kantar Media $4,650,000,000 $5
Nielsen Co. $4,842,992,880 $5
PLoS One (Kornfield et al.) $5,231,000,000 $5
Internet DTCA Kantar Media $181,000,000 $2
Nielsen Co. $56,180,283 $9
TVa Nielsen Co. $3,390,587,472 $3
Print Nielsen Co. $1,320,786,065 $1
Radio Nielsen Co. $66,798,340 $7
Outdoor Nielsen Co. $8,640,720 $1
aIncludes network, cable, syndicated, and spot TV ads. Excludes Spanish Language
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